Boehringer buys Actimis for $515

Boehringer Ingelheim is shelling out $515 million to acquire San Diego-based Actimis Pharmaceuticals, which is developing asthma and allergy drugs. Boehringer will acquire shares of Actimis as the company reaches milestones in the development of its lead compound AP768, an asthma and allergic rhinitisdrug that is currently in Phase I. The company will purchase all of Actimis' shares if the compound reaches Phase III.

"Actimis' compound provides an innovative addition to Boehringer Ingelheim's portfolio of development candidates for the potential treatment of respiratory diseases", said Dr. Andreas Barner, a Vice-Chairman at Boehringer Ingelheim. This is the first biotech takeover for Boehringer, which is Germany's second largest pharma company.

- check out this release for more
- read the Forbes report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.